Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16300
Revised: May 5, 2014
Accepted: June 13, 2014
Published online: November 21, 2014
Processing time: 315 Days and 17.8 Hours
AIM: To estimate and compare sex-specific screening polypectomy rates to quality benchmarks of 40% in men and 30% in women.
METHODS: A prospective cohort study was undertaken of patients aged 50-75, scheduled for colonoscopy, and covered by the Québec universal health insurance plan. Endoscopist and patient questionnaires were used to obtain screening and non-screening colonoscopy indications. Patient self-report was used to obtain history of gastrointestinal conditions/symptoms and prior colonoscopy. Sex-specific polypectomy rates (PRs) and 95%CI were calculated using Bayesian hierarchical logistic regression.
RESULTS: In total, 45 endoscopists and 2134 (mean age = 61, 50% female) of their patients participated. According to patients, screening PRs in males and females were 32.4% (95%CI: 23.8-41.8) and 19.4% (95%CI: 13.1-25.4), respectively. According to endoscopists, screening PRs in males and females were 30.2% (95%CI: 27.0-41.9) and 16.6% (95%CI: 16.3-28.6), respectively. Sex-specific PRs did not meet quality benchmarks at all ages except for: males aged 65-69 (patient screening indication), and males aged 70-74 (endoscopist screening indication). For all patients aged 50-54, none of the CI included the quality benchmarks.
CONCLUSION: Most sex-specific screening PRs in Québec were below quality benchmarks; PRs were especially low for all 50-54 year olds.
Core tip: Colonoscopy quality is essential to effective colorectal cancer screening. Polypectomy rates (PRs) of 40% in men and 30% in women have recently been proposed as screening colonoscopy quality indicators. In this prospective cohort study, we sought to estimate and compare screening PRs in Québec with published screening colonoscopy quality benchmarks. We found that sex-specific screening PRs benchmarks were rarely met. The very low screening PRs in patients aged 50-54 could not be explained by shorter than recommended screening intervals. Further research is needed to understand the discrepancy between quality benchmarks and clinical practice.